<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05119647</url>
  </required_header>
  <id_info>
    <org_study_id>ZHTQ2021001</org_study_id>
    <nct_id>NCT05119647</nct_id>
  </id_info>
  <brief_title>A Single-Arm Objective Performance Criteria Trail For Intracranial Thrombus Aspiration Catheter</brief_title>
  <official_title>The Efficacy and Safety Study of Thrombus Aspiration Catheter(Ton-bridgeMT) on Endovascular Treatment of Acute Ischemic Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhuhai Tonbridge Medical Tech. Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhuhai Tonbridge Medical Tech. Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective multicenter, single-arm objective performance criteria trail to assess&#xD;
      the efficacy and safety of the the thrombus aspiration catheter.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is conducted in 15 centers all around China, aiming at recruiting 155 patients with&#xD;
      acute stroke caused by artery occlusion.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2022</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Successful recanalization rate within three-times aspiration</measure>
    <time_frame>Up to 90 days</time_frame>
    <description>Successful recanalization is defined as modified Thrombolysis In Cerebral Infarction scale(mTICI) 2b or 3 evaluated by Digital subtraction angiography (DSA).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Successful recanalization rate within three-times aspiration</measure>
    <time_frame>Intraoperation</time_frame>
    <description>Successful recanalization is defined as mTICI 2b or 3 evaluated by DSA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Successful recanalization rate beyond three-times aspiration</measure>
    <time_frame>Intraoperation</time_frame>
    <description>Successful recanalization is defined as mTICI 2b or 3 evaluated by DSA. Auxiliary device such as stent could be used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>National Institute of Health stroke scale(NIHSS)</measure>
    <time_frame>72 hours / 7 days</time_frame>
    <description>NIHSS score in 72 hours and 7 days(or the day when patients discharged, depends on which day is earlier) will be compared.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Modified Rankin Scale(mRS) score less than 3</measure>
    <time_frame>90 days</time_frame>
    <description>The mRS score is assessed in 90 days follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device delivery performance</measure>
    <time_frame>Intraoperation</time_frame>
    <description>Device delivery performance including transport and pullback performance, which is ranked excellent/good/normal/bad.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of symptomatic intracranial hemorrhage</measure>
    <time_frame>72 hours</time_frame>
    <description>National Institute of Health stroke scale(NIHSS) increased by at least 4 compared with the baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death rate</measure>
    <time_frame>Up to 90 days</time_frame>
    <description>Subjects who died from any cause would be counted.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of AE</measure>
    <time_frame>Up to 90 days</time_frame>
    <description>The definition of AE(Adverse Event) refers to ISO 14155</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of SAE</measure>
    <time_frame>Up to 90 days</time_frame>
    <description>The definition of SAE (Serious Adverse Event) refers to ISO 14155</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of medical device deficiency</measure>
    <time_frame>Up to 90 days</time_frame>
    <description>Medical device deficiency refer to the unreasonable risks of medical devices that may endanger human health and life safety under normal use in the process of clinical trials, such as label errors, quality problems, malfunctions, etc.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">155</enrollment>
  <condition>Acute Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>Patient Recruited</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Since this is a single-arm objective performance criteria trail, patients with acute stoke caused by artery occlusion shall not be divided into two groups.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Thrombus Aspiration Catheter(Ton-bridgeMT)</intervention_name>
    <description>Thrombus Aspiration Catheter is a developed technique for treating acute stroke caused by artery occlusion. The catheter(Ton-bridgeMT) was specially designed for those patients who experience acute stroke within 24 hours.</description>
    <arm_group_label>Patient Recruited</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥18 years;&#xD;
&#xD;
          -  Baseline NIHSS score ≥6;&#xD;
&#xD;
          -  Subject has acute occlusion located in Vertebral artery(VA) / Internal Carotid Artery&#xD;
             (ICA) / M1or M2 segment of Middle Cerebral Artery (MCA) / Basilar artery (BA)&#xD;
             diagnosed by DSA;&#xD;
&#xD;
          -  Femoral artery puncture is expected to be completed within 24 hours of onset；&#xD;
&#xD;
          -  mRS score≤ 2;&#xD;
&#xD;
          -  Subject or legal representative is able to understand the purpose of study, agrees to&#xD;
             comply with protocol requirements and has provided written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Chronic occlusion in the target area;&#xD;
&#xD;
          -  Epilepsy at the time of stroke；&#xD;
&#xD;
          -  Bleeding from the gastrointestinal or urinary system in the past three weeks；&#xD;
&#xD;
          -  After drug control, systolic blood pressure was greater than 185mmhg and / or&#xD;
             diastolic blood pressure was greater than 110mmhg;&#xD;
&#xD;
          -  International Normalized Ratio(INR)&gt;3;&#xD;
&#xD;
          -  Random blood glucose &lt; 2.7mmol/L or &gt; 22.2mmol/L;&#xD;
&#xD;
          -  Heart, lung, liver, kidney failure or other serious diseases (such as brain tumors, -&#xD;
             systemic infection, active disseminated intravascular coagulation, myocardial&#xD;
             infarction within 12 months before enrollment, history of severe mental illness);&#xD;
&#xD;
          -  Tortuous lesion / severe stenosis in the starting segment of the carotid artery /&#xD;
             Carotid dissection / Arteritis judged by researchers that is not suitable for the&#xD;
             procedure;&#xD;
&#xD;
          -  Acute occlusion of bilateral carotid arteries；&#xD;
&#xD;
          -  Intracranial hemorrhage or massive infarction diagnosed by CT or MR;&#xD;
&#xD;
          -  History of allergies to antiplatelet drugs, anticoagulants, anesthetics, contrast&#xD;
             agents;&#xD;
&#xD;
          -  Expected life &lt;12 months;&#xD;
&#xD;
          -  Female subjects who are pregnant or planning to become pregnant or lactate within the&#xD;
             study period;&#xD;
&#xD;
          -  Subject has participated in any other drug or medical device clinical trials in 1&#xD;
             month before signing informed consent;&#xD;
&#xD;
          -  Other circumstances judged by researchers that are not suitable for enrollment .&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Liqun Jiao</last_name>
    <role>Principal Investigator</role>
    <affiliation>Xuanwu Hospital, Beijing</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peiyi Li</last_name>
    <phone>13840536851</phone>
    <email>py.li@ton-bridge.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dingrong Pan</last_name>
    <phone>18868106641</phone>
    <email>dr.pan@ton-bridge.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The First Affiliated Hospital of USTC</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Wei Hu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhuhai people's hospital</name>
      <address>
        <city>Zhuhai</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Ligong Lu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Nanning People's hospital</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Tong Li</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cangzhou central hospital</name>
      <address>
        <city>Cangzhou</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yongchang Liu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hunan Provincial People's Hospital</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Hua Xiang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ganzhou Municipal Hospital</name>
      <address>
        <city>Ganzhou</city>
        <state>Jiangxi</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Hanwen Liu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Central Hospital Affiliated to Shangdong First Medical University</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yanxin Zhao</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>First People's Hospital of Jinan</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jianfeng Chu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second People's Hospital of Liaocheng</name>
      <address>
        <city>Liaocheng</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Xinqiang Wang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rizhao central Hospital</name>
      <address>
        <city>Rizhao</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Maoxu Li</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanxi Candiovascular hospital</name>
      <address>
        <city>Taiyuan</city>
        <state>Shanxi</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Dong Kuai</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>School of medicine UESTC</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Fuqiang Guo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zigong Third People's Hospital</name>
      <address>
        <city>Zigong</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Li Wang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Zhejiang University School of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jing Xu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xuanwu hospital Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Liqun Jiao</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 3, 2021</study_first_submitted>
  <study_first_submitted_qc>November 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 15, 2021</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Stroke</keyword>
  <keyword>Aspiration</keyword>
  <keyword>Catheter</keyword>
  <keyword>Intracranial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

